ADVERTISEMENT
Search

 

Press Releases

 

7

Mar

2022

New Study: Medicare could save seniors billions by fixing Part D incentives

Author: Renee Kalu

WASHINGTON, DC and BESSEMER, AL—Plan sponsors and PBMs who manage prescription drug benefits under Medicare Part D are shifting costs and risks to America’s seniors and taxpayers by artificially inflating prescription drug costs at the pharmacy counter, according to a groundbreaking new study released today.

Comments (0)
Number of views (5548)
Article rating: No rating

18

Feb

2022

APhA expresses disappointment at failed Federal Trade Commission vote to study PBMs’ anticompetitive business practices

APhA urges the Federal Trade Commission (FTC) to reach a consensus to not only study, but fix the broken PBM marketplace

Author: Renee Kalu

WASHINGTON, D.C.—The American Pharmacists Association (APhA) issued the following statement in response to the FTC’s stalemate 2-2 vote today, which would have supported study of the competitive impact of contractual provisions, reimbursement adjustments, and other PBM practices affecting drug prices, including those practices that may disadvantage independent or specialty pharmacies.

Comments (0)
Number of views (3146)
Article rating: No rating

16

Feb

2022

APhA congratulates Robert Califf, MD, on confirmation as FDA Commissioner

Author: Renee Kalu

WASHINGTON, D.C.—The American Pharmacists Association (APhA) issued the following statement to congratulate Robert Califf, MD, on his confirmation to serve once again as commissioner of FDA. APhA looks forward to working with both Califf and the FDA to ensure the safety, efficacy, and security of medications for our nation’s pharmacy patients.

Comments (0)
Number of views (2731)
Article rating: No rating

21

Jan

2022

APhA urges plans and payers to immediately act to ensure patients have access to lifesaving COVID-19 oral medications via their pharmacist

Author: Renee Kalu

WASHINGTON, D.C.—The American Pharmacists Association (APhA) issued the following statement in response to plans and payers, including PBMs, setting the dispensing fee for new COVID‐19 oral antiviral therapies below pharmacies’ costs to dispense these lifesaving medications:

Comments (0)
Number of views (3115)
Article rating: No rating
RSS
123
ADVERTISEMENT